Company Overview - DigitalBridge manages \$96 billion in AUM and \$36 billion in FEEUM as of December 31, 2024 [34] - The company has over 40 portfolio companies and over 25 years of experience in the digital infrastructure sector [34] - DigitalBridge targets revenue growth of >25% and cash flow metrics to increase >90% in 2024 [55] Financial Performance - Fee revenue increased by 37% from \$744 million in 4Q23 to \$1016 million in 4Q24 [84] - Fee revenue increased by 23% from \$2671 million in 2023 to \$3298 million in 2024 [84] - Fee Related Earnings (FRE) increased by 34% from \$264 million in 4Q23 to \$354 million in 4Q24 [84] - FRE increased by 31% from \$818 million in 2023 to \$1071 million in 2024 [84] - Distributable Earnings (DE) increased by 11% from \$179 million in 4Q23 to \$199 million in 4Q24 [84] - Distributable Earnings (DE) increased by 8% from \$486 million in 2023 to \$525 million in 2024 [84] Future Outlook - The company projects FEEUM to reach approximately \$40 billion in 2025 and \$60-70 billion by 2028 [94] - The company anticipates FRE to grow by 10%-20% in 2025 [94] - The company targets a FRE margin in the mid-40s% by 2028 [87, 94]

Financial Performance & Growth Strategy - Pacira reported $701 million in revenue in 2024[10] - The company aims for double-digit compounded annual growth rate[15, 18] - Pacira anticipates a 5-percentage point gross margin improvement over 2024[15, 18] - First quarter of 2025 (1Q25) total revenue reached $169 million, with EXPAREL contributing $137 million, ZILRETTA $23 million, and iovera° $5 million[109] - Non-GAAP gross margins for 1Q25 were 81%, and adjusted EBITDA was $44 million[109] - Pacira's cash and investments exceeded $493 million as of March 31, 2025[109] Product Portfolio & Pipeline - Pacira has treated over 16 million patients with its three best-in-class products[10] - The company is expanding its clinical pipeline with 5 novel programs in development[15, 18] - Pacira is establishing 5 partnerships, including pipeline and commercial agreements[15, 18] PCRX-201 & Osteoarthritis (OA) Treatment - The global OA injectables market is projected to grow at a CAGR of 682% from 2024 to 2030[86] - PCRX-201 demonstrated that over 70% of patients saw a greater than 50% improvement in pain and stiffness vs baseline at week 16 and 78[75]

Company Overview and Milestones - Sharps Technology was founded in 2017 and completed its IPO in 2022, raising $16 million[3] - The company acquired SafeGard Medical in Hungary in July 2022, a facility producing specialty safety syringes[3] - In May 2024, Sharps Technology signed an Asset and Syringe Sales Agreement with Nephron and InjectEZ[4] - A $20 million underwritten public offering was closed in January 2025[5] Manufacturing and Product Line - The company has an operational manufacturing facility in Hungary (~40k Sq Ft) and a pending facility in Columbia, South Carolina (~100k Sq Ft)[10, 12] - The Hungary facility has a capacity of 45 million units, expandable to 200 million units[23] - The South Carolina facility is expected to have a capacity of 60 million units per year, expandable to 90 million units per year[28, 29] - Sharps Technology has a product line of patented smart safety syringe systems, including Securegard, Provensa, Sologard Locking +, and Sologard[6, 14] Sales and Financials - A multi-year agreement with a U S leader in IV flushing solutions is expected to generate over $50 million in revenue over five years, with first shipments in Q2 2025[4] - The company received a $400,000 purchase order in June 2025 and began shipments for SoloGard[34] - The agreement for SoloGard could involve +500 million units over five years[36] - The company has $11.9 million in cash and no debt[67] Market Overview - The global syringe market was valued at $22.5 billion in 2023, with a CAGR of approximately 9.2%[39, 40] - The disposable syringe market was valued at $13.1 billion in 2023, with a CAGR of approximately 6.1%[43, 44] - The prefillable syringe market was valued at $8.1 billion in 2023[39]

Clinical Trial Results of PLN-74809 - PLN-74809 demonstrated dose-dependent target engagement and TGF-β suppression in prior studies[24] - PLN-74809 was well-tolerated over 12 weeks of treatment in the INTEGRIS-IPF trial[32] - PLN-74809-treated patients experienced an 80% reduction in FVC decline over 12 weeks (-15.1 mL, Pooled Active Groups) compared to Placebo (-74.1 mL)[33] - An improvement in FVC (+24.6 mL) was observed in PLN-74809 80 mg dose cohort[34] - A dose-dependent antifibrotic effect was seen on QLF Imaging, with no progression in the 160 mg group at Week 12[34] - PLN-74809 decreased serum biomarkers of collagen synthesis (PRO-C3 and PRO-C6) relative to placebo[34] Safety and Tolerability - Most Treatment Emergent Adverse Events (TEAEs) were mild or moderate in severity, and there were no discontinuations due to adverse events, deaths, or drug-related Serious Adverse Events (SAEs)[34] - The most frequent TEAE seen was diarrhea, but it was only observed in patients on standard of care[54] FVC Analysis - PLN-74809-treated participants experienced a benefit in FVC change from Baseline to Week 12 (-15.1 mL for pooled PLN-74809 group) compared to those on placebo (-74.1 mL)[77] - A dose-dependent reduction was observed in the proportion of participants with FVCpp decline of ≥10%[34] - Quantitative Lung Fibrosis (QLF) imaging showed a dose-dependent antifibrotic effect, with no progression in the 160 mg group at Week 12 based on mean change from baseline[84]

Company Highlights and Financial Position - Pliant Therapeutics has raised over $625 million to date, including a 2020 IPO and a follow-on offering in July 2022 [8] - The company's cash balance was $360 million as of September 30, 2022, funding operations to mid-2025 [8] Bexotegrast (PLN-74809) in IPF and PSC - Bexotegrast is in Phase 2a development for Idiopathic Pulmonary Fibrosis (IPF) and Primary Sclerosing Cholangitis (PSC) [8] - In the INTEGRIS-IPF study, bexotegrast treatment resulted in an 80% reduction in FVC decline over 12 weeks compared to placebo (-15.1 mL vs -74.1 mL) [47, 48] - In the INTEGRIS-IPF study, an actual improvement in FVC (+24.6 mL) was observed in the 80 mg dose cohort [48] - In the INTEGRIS-IPF study, the proportion of participants with FVCpp decline ≥ 10% was 4.5% in the 160 mg group compared to 17.4% in the placebo group [55] PLN-101095 for Solid Tumors - An IND has been submitted for PLN-101095, a potential first-in-class small molecule dual αVβ8/αVβ1 inhibitor addressing ICI resistance in solid tumors, with Phase 1 initiation expected in 2Q 2023 [8, 9] - PLN-101095, combined with αPD-1, demonstrated high tumor growth inhibition in the EMT6 syngeneic mouse model [91] Market Opportunity in IPF - The two marketed agents for IPF, Esbriet® and Ofev®, had >$3 billion in total global revenues in 2021 [17]

Company Overview - AeroVironment is a technology innovator in multiple industries including Small Unmanned Aircraft Systems (UAS), Atmospheric Satellites, Tactical Missile Systems, and EV Charging Solutions[9, 10] - The company's revenue in Fiscal Year 2016 was $264 million[11] - From 2004 to 2016, AeroVironment achieved a sales Compound Annual Growth Rate (CAGR) of 15%[11] - AeroVironment holds more than 85% share of all unmanned aircraft in the U S Department of Defense (DoD) inventory (in units)[11] Business Segments - Unmanned Aircraft Systems (UAS) accounted for 89% of the company's total revenue in FY2016, with a revenue CAGR of 15% from FY2004 to FY2016[28] - Efficient Energy Systems (EES) contributed 11% of the total company revenue in FY2016[30] Financial Performance - In FY2016, the company's revenue was $264 1 million[61] - The gross margin for FY2016 was 42% ($112 1 million)[61] - The profit from operations for FY2016 was $9 7 million, representing a 4% margin[61] - The company has a strong balance sheet with $261 million in cash and investments and no debt[62] Market Opportunities - The U S government is projected to purchase $3 to $5 billion annual commercial satellite capacity within ten years[46] - Potential market value for EV charging systems based on 7 5% EV adoption is $1 3 billion in the United States and $4 1 billion globally[49]

Financial Performance & Growth - AeroVironment's fiscal year 2019 revenue was $314.3 million[42] - The company's gross margin for fiscal year 2019 was 41%[42] - Diluted earnings per share (EPS) attributable to AeroVironment for fiscal year 2019 was $1.74[42] - The company has $333 million in cash, short and long term investments[43] Revenue Breakdown by Segment - Small Unmanned Aircraft Systems accounted for 58% of fiscal year 2019 company revenue[21] - High-Altitude Pseudo-Satellite (HAPS) Systems contributed 18% of fiscal year 2019 company revenue[27] - Tactical Missile Systems represented 21% of fiscal year 2019 company revenue[31] International Revenue - International revenue has grown from 7% in FY15 to 52% in FY19 of total revenue[23]

Financial Performance - AeroVironment achieved record fourth quarter revenue of $135 million[6] - The company's fiscal year revenue reached $367 million[6], a 17% year-over-year increase[8], driven by higher small UAS, "other," and HAPS revenue[8] - Gross profit for the fiscal year was $153.1 million[8], a 19% increase[8] - The funded backlog reached a record $208 million[6], a 27% increase[8] - Diluted EPS was $1.72, compared to $1.74 in the previous year, which included a $0.26 per share one-time gain from litigation settlement[8] - Non-GAAP diluted EPS was $1.84, an increase of $0.36, including $0.12 in acquisition-related expenses and amortization of intangible assets[8] Strategic Progress - AeroVironment strengthened its leadership position in multiple markets[6] - Small UAS revenue reached $226 million, driven by strong domestic demand[13] - The company expanded its international reach to a total of 50 allied customers[13] - The contract value of the HAPS program grew to $166 million[13] Fiscal Year 2021 Expectations - AeroVironment anticipates revenue between $390 million and $410 million for fiscal year 2021[17, 18] - The company expects an operating income margin of 12% to 12.5%[18] - Diluted earnings per share are projected to be between $1.65 and $1.85[18] - Non-GAAP diluted earnings per share are expected to be between $1.74 and $1.94[18]

Financial Performance & Growth - AeroVironment's annual revenue increased from $367 million in 2020 to $716 million in 2024[9] - The company projects FY25 revenue between $790 million and $820 million, representing approximately 12% growth[154] - Adjusted EBITDA is expected to grow by 16% from $128 million in FY24 to between $143 million and $153 million in FY25[154] - Long-term organic revenue growth is projected at 10% to 15%, with total growth exceeding 20% through inorganic opportunities[156] Market & Strategy - The global defense budget is experiencing a post-Ukraine CAGR of 54% [17] - AeroVironment operates in markets with a total addressable market (TAM) exceeding $12 billion[19] - The company aims to expand its TAM from $12 billion+ to $30 billion+ by targeting adjacent markets and leveraging core capabilities[161, 163] - R&D expenses are expected to be between 12% and 13% of revenues in FY25[154] Key Programs & Capabilities - Loitering Munitions and Uncrewed Systems are key growth drivers, with multiple $1 billion+ opportunities on the horizon[56] - The Tomahawk Robotics GCS integrates AV vehicles and third-party systems, offering a common control solution[110] - AV's Autonomy suite, including ARK, AVACORE, and SPOTR Edge, delivers advanced AI and autonomy capabilities[87]

Company Overview - AeroVironment (AV) has a pro forma adjusted revenue of approximately $2 billion in FY26 [8] - The company's market capitalization is $8 billion as of May 31, 2025 [10] - AV has fielded over 42,000 platforms in demanding environments [7] - AV sells to over 100 countries [9] Strategic Positioning and Growth - AV's total addressable market exceeds $50 billion [23] - The U S DoD is pushing for $150 billion in additional spending [22, 26] - No single area is expected to contribute more than 30% of FY26 pro-forma revenue [30] Innovation and Technology - Nearly $3 billion has been invested in hardware and software over the past decade [21, 31] - AV has delivered over 40,000 units, continually refined through operational feedback [31] BlueHalo Acquisition - The acquisition of BlueHalo closed on May 1, 2025 [13] - The acquisition is expected to be accretive to Revenue, Adjusted EBITDA, and non-GAAP EPS in the first full year post-close [16] Cost Advantage - Ukraine has fired approximately $36 million worth of Switchblade 600 munitions to destroy over $2.5 billion worth of enemy equipment [67]